Table 2.
Median number (range) of circulating T-lymphocyte subsets three (M3) and six (M6) months after HSCT (cells × 103/μl).
| M3 | M6 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| N | CD3+ | CD4+ | CD8+ | N | CD3+ | CD4+ | CD8+ | ||
| All patients | Haplo | 33 | 264 (0–2666) | 68 (0–1767) | 80 (0–1666) | 30 | 610 (140–2992) | 242 (88–760) | 270 (14–2596) |
| UCBT | 23 | 540 (180–4661) | 190 (72–885) | 280 (18–4092) | 21 | 852 (352–6440) | 336 (105–1288) | 456 (80–5152) | |
| p | 0.003 | 0.005 | 0.010 | 0.058 | 0.022 | 0.151 | |||
| Malignant Haplo-HSCT | Relapse | 8 | 279 (4–572) | 29 (0–264) | 84 (0–308) | 7 | 867 (154–2460) | 234 (98–369) | 480 (14–2132) |
| CR | 19 | 252 (0–2666) | 138 (0–1767) | 63 (0–1666) | 17 | 560 (140–2992) | 273 (88–546) | 248 (14–2596) | |
| p | 0.894 | 0.300 | 0.831 | 0.193 | 0.975 | 0.075 | |||
| Malignant UCBT | Relapse | 3 | 1040 (266–4661) | 234 (91–885) | 819 (154–3540) | 3 | 1250 (852–1288) | 324 (250–529) | 759 (516–1000) |
| CR | 15 | 715 (180–4465) | 153 (72–616) | 476 (18–4092) | 14 | 811 (352–6440) | 322 (105–1288) | 442 (80–5152) | |
| p | 0.441 | 0.594 | 0.441 | 0.314 | 0.801 | 0.313 | |||
M3 stands for Month 3; M6, Month 6, and CR, Complete remission.